Mersana Therapeutics (MRSN) Misses Q4 EPS by 28c, Revenues Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Mersana Therapeutics (MRSN) Misses Q4 EPS by 28c, Revenues Miss

Mersana (MRSN) PT Lowered to $11 at Wedbush

March 12, 2019 7:19 AM EDT

Wedbush analyst David Nierengarten lowered the price target on Mersana (NASDAQ: MRSN) to $11.00 (from $15.00) while maintaining a Outperform rating.

Ph 1b dose escalation data from MRSNs XMT-1536 is expected in 2Q19MRSN set to unveil their next clinical candidate in H2:19... More